A year ago, Intarcia Therapeutics Inc. was close to a deal that would have licensed its implantable diabetes drug to a Big Pharma partner. Instead of sharing rights to its compound, however, Intarcia has raised a massive $210 million equity and debt round from private investors, one of the largest in recent memory for a privately-held life sciences company. The new funds will allow it to begin Phase III trials on a program that could see approval by 2016.
In a deal announced Nov. 15, five new investors backed Intarcia with $160 million in equity funding and supplied $50...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?